Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.
[More]
Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.
[More]
Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).
[More]
Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.
[More]
News outlets continue plumbing newly released federal data that details for the first time what hospitals charge for some of the most common in-patient procedures.
[More]
Today's headlines include reports that Health and Human Services Secretary Kathleen Sebelius has been seeking out funds from private sources to support efforts to publicize the health law.
[More]
Celiac disease is estimated to affect one out of 141 of Americans, or just under 1 percent of the population.
[More]
Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, may be detected and monitored more effectively in the future with positron emission tomography/computed tomography, according to research published in the May issue of The Journal of Nuclear Medicine.
[More]
A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
[More]
Acute pancreatitis is an inflammation of the pancreas which leads to leakage of pancreatic enzymes. Apart from certain drugs such as GLP-1 based therapies, the most common causes of pancreatitis are Gallstones and Alcohol use.
[More]
For women with abdominal pain or vaginal bleeding during early pregnancy, patient history and clinical examination alone are insufficient to indicate or eliminate the possibility of ectopic pregnancy, while transvaginal sonography appears to be the single best diagnostic method for evaluating suspected ectopic pregnancy, according to an analysis of previous studies reported in the April 24 issue of JAMA.
[More]
Vertex Pharmaceuticals Incorporated today announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study evaluating the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus infection who have the IL28B CC genotype.
[More]
ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.
[More]
A study led by researchers at the Perelman School of Medicine at the University of Pennsylvania and Boston University School of Medicine has found that nearly one quarter of patients may return to the emergency department within 30 days of being discharged from a hospitalization.
[More]
Getting your appendix out can cost between $2,000 and $180,000. Hip replacements run from $10,000 to more than $100,000. Hospitals, we have also learned, frequently mark up the price of cotton swabs and routine X-rays by 300 or 400 percent, with most patients oblivious to the reason their health care bills are so large.
[More]
Lipid Therapeutics announces today that it has successfully filed its first US IND for its lead product LT-02 and is now in a position to proceed with a planned Phase III trial in the US in mild-moderate ulcerative colitis patients. The LT-02 IND was subject to the FDA's customary 30 day review period.
[More]
Lynch syndrome is one of the inherited cancer syndromes characterized by the development of colorectal cancer, endometrial cancer and other cancers at an early age.
[More]
A Spectrum Health clinical trial has found that fecal microbial transplantation (FMT) has resulted in the improvement or absence of symptoms in most pediatric patients with active ulcerative colitis.
[More]
Vertex Pharmaceuticals Incorporated today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb Company to conduct Phase 2 studies of once-daily all-oral treatment regimens containing Vertex's nucleotide analogue hepatitis C virus polymerase inhibitor VX-135 and Bristol-Myers Squibb's NS5A replication complex inhibitor daclatasvir for the treatment of hepatitis C.
[More]
Strong new biochemical evidence exists showing that the cereal grain sorghum is a safe food for people with celiac disease, who must avoid wheat and certain other grains, scientists are reporting.
[More]